These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29532913)

  • 21. Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia.
    Poza M; Íñiguez R; Zamanillo I; Redondo S; Alonso R; Martínez-López J; Jiménez-Ubieto A
    Ther Adv Hematol; 2021; 12():20406207211039326. PubMed ID: 34471509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Waldenström macroglobulinaemia and intestinal lymphangiectasia.
    Cooke RE; Kalnins RM; Ho WK
    Br J Haematol; 2014 Nov; 167(3):292. PubMed ID: 25039993
    [No Abstract]   [Full Text] [Related]  

  • 23. A role for intravenous immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM gammopathy.
    Lavin M; Ryan K; White B; Byrne M; O'Connell NM; O'Donnell JS
    Haemophilia; 2018 Jan; 24(1):e22-e25. PubMed ID: 29168278
    [No Abstract]   [Full Text] [Related]  

  • 24. Von Willebrand factor, factor VIII and the factor VIII/von Willebrand factor complex.
    Ingerslev J
    Dan Med Bull; 1990 Oct; 37(5):385-406. PubMed ID: 2125548
    [No Abstract]   [Full Text] [Related]  

  • 25. [Evaluation of a new automated method for von Willebrand factor antigen measurement: the STA-Liatest vWF].
    Veyradier A; Fressinaud E; Sigaud M; Wolf M; Meyer D
    Ann Biol Clin (Paris); 1999 May; 57(3):364-8. PubMed ID: 10377492
    [No Abstract]   [Full Text] [Related]  

  • 26. Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag).
    Favaloro EJ; Mohammed S; Patzke J
    Methods Mol Biol; 2017; 1646():403-416. PubMed ID: 28804844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired von Willebrand's syndrome in the course of Waldenström's disease.
    Mazurier C; Parquet-Gernez A; Descamps J; Bauters F; Goudemand M
    Thromb Haemost; 1980 Dec; 44(3):115-8. PubMed ID: 6781094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenström macroglobulinaemia.
    Wang SC; Huang WT; Ma MC; Medeiros LJ; Chang KC
    Pathology; 2019 Aug; 51(5):549-553. PubMed ID: 31202483
    [No Abstract]   [Full Text] [Related]  

  • 29. [Method of determining von Willebrand factor activity].
    Papaian LP
    Lab Delo; 1982; (5):275-8. PubMed ID: 6178881
    [No Abstract]   [Full Text] [Related]  

  • 30. [Waldenström macroglobulinemia].
    Telek B; Batár P; Váróczy L; Gergely L; Rejtő L; Szász R; Miltényi Z; Simon Z; Udvardy M; Illés A
    Orv Hetil; 2013 Dec; 154(50):1970-4. PubMed ID: 24317355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases.
    Mital A; Prejzner W; Hellmann A
    Adv Clin Exp Med; 2015; 24(6):1001-6. PubMed ID: 26771972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assays for von Willebrand factor functional activity: a UK NEQAS survey. National External Quality Assessment Scheme.
    Preston FE
    Thromb Haemost; 1998 Nov; 80(5):863. PubMed ID: 9843188
    [No Abstract]   [Full Text] [Related]  

  • 33. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
    Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
    Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Case of Waldenstrom Macroglobulinemia with Temporary Appearance of 7S IgM Half Molecule.
    Imoto M; Yoshida K; Maeda Y; Nakae KI; Kudo M; Sakurabayashi I; Yamada T; Kamisako T
    Clin Lab; 2017 May; 63(5):983-989. PubMed ID: 28627827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pseudohypercreatininemia due to positive interference in enzymatic creatinine measurements caused by monoclonal IgM in patients with Waldenström's macroglobulinemia.
    Hummel KM; von Ahsen N; Kühn RB; Kaboth U; Grunewald RW; Oellerich M; Müller GA
    Nephron; 2000 Oct; 86(2):188-9. PubMed ID: 11014992
    [No Abstract]   [Full Text] [Related]  

  • 36. Fluctuating von Willebrand Factor Activity in a Young Adult.
    Parsons MG; Merrill AE
    Clin Chem; 2024 Sep; 70(9):1188-1189. PubMed ID: 39222936
    [No Abstract]   [Full Text] [Related]  

  • 37. Determination of von Willebrand factor activity with collagen-binding assay and diagnosis of von Willebrand disease: effect of collagen source and coating conditions.
    Paczuski R
    J Lab Clin Med; 2002 Oct; 140(4):250-4. PubMed ID: 12389023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
    Pasricha SR; Juneja SK; Westerman DA; Came NA
    J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histidine based adsorbents for selective removal of monoclonal immunoglobulin IgM antibodies from Waldenstrom's macroglobulinemia patient sera: a preliminary study.
    Srour M; Kassab I; Matta H; Elkak A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Aug; 932():1-5. PubMed ID: 23811496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of 7s IgM in monoclonal IgM diseases.
    Carter PM; Hobbs JR
    Br Med J; 1971 May; 2(5756):260-1. PubMed ID: 4995405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.